Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance
To evaluate the relation of cluster of differentiation 44 (CD44) expression with clinicopathological features of gastric adenocarcinoma, and also its effect on prognosis with an emphasis on the differences between intestinal and diffuse types. From 2000 to 2006, 100 patients with gastric adenocarcin...
Saved in:
Cover
Loading…
Summary: | To evaluate the relation of cluster of differentiation 44 (CD44) expression with clinicopathological features of gastric adenocarcinoma, and also its effect on prognosis with an emphasis on the differences between intestinal and diffuse types.
From 2000 to 2006, 100 patients with gastric adenocarcinoma, who had undergone total or subtotal gastrectomy without any prior treatment, were studied. Haematoxylin and eosin (HE) staining was used for histological evaluation, including the type (Lauren's classification) and grading of the tumor. The expression of CD44 in the gastric adenocarcinoma mucosa and the adjacent mucosa were determined by immunohistochemistry. The survival analysis was obtained using the Kaplan-Meier test.
Of 100 patients, 74 (74%) patients were male. The tumors were categorized as intestinal type (78%) or diffuse type (22%). Sixty-five percent of patients were CD44-positive. CD44 expression was not detected in normal gastric mucosa. Rather, CD44 was more commonly expressed in the intestinal subtype (P=0.002). A significant relation was seen between the grade of tumor and the expression of CD44 (P=0.014). The survival analysis showed a poor prognosis of patients with CD44-positive tumors (P=0.008); and this was more prominent in the intestinal (P=0.001) rather than diffuse type.
Cell adhesion molecule CD44 is highly expressed in gastric adenocarcinoma. CD44 expression is correlated with a poor prognosis in patients with the intestinal type of gastric adenocarcinoma. CD44 can, therefore, be utilized as a prognostic marker for this group of patients. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Correspondence to: Mostafa Jafarzadeh, MD, Gastric Cancer Research Group, Mashhad University of Medical Sciences, 51, Jami Street, Sajad Blvd, PO Box 91865-335, Mashhad, Iran. mostafa.jafarzadeh@gmail.com Telephone: +98-915-1106494 Fax: +98-511-6065742 Author contributions: Sima HR, Ghaffarzadehgan K, Raziee HR, Esmaili-Shandiz E and Jafarzadeh M designed the research; Ghaffarzadehgan K, Sima HR, Raziee HR, Hosseinnezhad H, Taghizadeh-Kermani A and Moaven O performed the research; Raziee HR, Bahrani M, and Jafarzadeh M analyzed the data; Jafarzadeh M, Raziee HR and Hosseinnezhad H organized the figures and patient data; Esmaili-Shandiz E, Hosseinnezhad H, Moaven O helped organize the paper; Ghaffarzadehgan K, Jafarzadeh M, Raziee HR and Sima HR wrote and corrected the paper. |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.14.6376 |